On Feb. 22, 2021, Novavax and the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the U.S. and Mexico to evaluate the efficacy, safety and immunogenicity of the companyﾒs COVID-19 vaccine. Novavax had previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.